title: Preparation and characterisation of bFGF-encapsulated liposomes and evaluation of wound-healing activities in the rat.
abstract: OBJECTIVE
  The basic fibroblast growth factor (bFGF) has a very short half-life in vivo, and this limits its therapeutic value for frequent administration. Liposome technology was used to improve the stability of bFGF and to prolong its effects in vivo.
  
  
  METHODS
  bFGF-encapsulated liposomes (bFGF-lip) were prepared using the pH gradient method. Four critical factors were investigated including concentration of citric acid solution, incubation time of blank liposomes, incubation temperature and sonication time. The pharmacodynamics of bFGF-lip was investigated by establishing a deep second-degree burns model in rats.
  
  
  RESULTS
  The optimal bFGF-lip were characterised by high entrapment efficiency (79.88 ± 3.37%), good physical stability (K(E): 1.02 ± 0.413%) and high bioactivity ((6.147 ± 0.769) × 10(5) IU ml(-1)). The middle dose of bFGF-lip (60 IU ml(-1)) demonstrated the fastest tissue collagen generation as well as the earliest and highest tumour growth factor (TGF)-β1 and dermal cell proliferation (proliferating cell nuclear antigen (PCNA)) expression as compared with other treatments.
  
  
  CONCLUSIONS
  Results of the present study imply that bFGF-lip have promising prospects for application in wound-healing therapies.
authors.affiliation: Biopharmaceutical R&D Center, Jinan University, Guangzhou 510632, People's Republic of China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Xiang
authors.forename: Jian
authors.initials: J
authors.lastname: Xiao
authors.forename: Hongbo
authors.initials: H
authors.lastname: Zhang
authors.forename: Xie
authors.initials: X
authors.lastname: Zhang
authors.forename: Meifei
authors.initials: M
authors.lastname: Lu
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Zhijian
authors.initials: Z
authors.lastname: Su
authors.forename: Wen
authors.initials: W
authors.lastname: Zhao
authors.forename: Cai
authors.initials: C
authors.lastname: Lin
authors.forename: Yadong
authors.initials: Y
authors.lastname: Huang
authors.forename: Xiaokun
authors.initials: X
authors.lastname: Li
mesh_terms: D000818:Animals; D002056:Burns / Q000188:drug therapy* / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000187:drug effects; D004195:Disease Models, Animal; D016503:Drug Delivery Systems / Q000379:methods; D004797:Enzyme-Linked Immunosorbent Assay; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008081:Liposomes; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D008081:Liposomes; D018809:Proliferating Cell Nuclear Antigen; D053773:Transforming Growth Factor beta1; D016222:Fibroblast Growth Factor 2; D003094:Collagen